Literature DB >> 14684557

Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice.

J David Holtzclaw1, Daniel Jack, Samuel M Aguayo, James R Eckman, Jesse Roman, Lewis L Hsu.   

Abstract

Some suggest that sickle cell disease (SCD) is associated with a "proinflammatory state" that predisposes patients to acute chest syndrome in the setting of triggering factors. Conflicting data emerged when inflammation markers in SCD were compared with healthy individuals. Therefore, we examined transgenic sickle and control mice at baseline and with endotoxin (LPS) intraperitoneal injection to determine whether a proinflammatory state truly exists. At baseline, sickle mice had elevated levels of circulating leukocytes and soluble vascular cell adhesion molecule 1 (sVCAM-1). No other differences were observed at baseline or in response to saline. However, LPS challenge was associated with significant increases in mortality (p<0.05), airway tone (p<0.03), serum and bronchoalveolar lavage levels of cytokines tumor necrosis factor-alpha (p<0.03), interleukin-1beta (p<0.02), and sVCAM-1 (p<0.01) in sickle mice compared with control subjects. Furthermore, 4 hours after LPS, microarray analysis identified 413 genes differentially expressed in the sickle mice (n=5) compared with only 7 in the control subjects (n=5). No difference in lung parenchyma was observed by light microscopy. This enhanced response to LPS suggests that the sickle red blood cell confers a subclinical "proinflammatory state." This enhanced response to inflammatory insult, particularly by adhesion molecules such as sVCAM-1, could play a role in the increased susceptibility to pulmonary dysfunction that has been observed clinically in SCD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684557     DOI: 10.1164/rccm.200302-224OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  28 in total

1.  The sickle cell mouse lung: proinflammatory and primed for allergic inflammation.

Authors:  Biree Andemariam; Alexander J Adami; Anurag Singh; Jeffrey T McNamara; Eric R Secor; Linda A Guernsey; Roger S Thrall
Journal:  Transl Res       Date:  2015-03-16       Impact factor: 7.012

Review 2.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

3.  Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.

Authors:  Margaret F Bennewitz; Maritza A Jimenez; Ravi Vats; Egemen Tutuncuoglu; Jude Jonassaint; Gregory J Kato; Mark T Gladwin; Prithu Sundd
Journal:  JCI Insight       Date:  2017-01-12

4.  Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.

Authors:  Robert S Nickel; Ifeyinwa Osunkwo; Aneesah Garrett; Jennifer Robertson; David R Archer; Daniel E L Promislow; John T Horan; Jeanne E Hendrickson; Leslie S Kean
Journal:  Br J Haematol       Date:  2015-03-05       Impact factor: 6.998

5.  Immunological role of CD4+CD28null T lymphocytes, natural killer cells, and interferon-gamma in pediatric patients with sickle cell disease: relation to disease severity and response to therapy.

Authors:  Mohsen Saleh ElAlfy; Amira Abdel Moneam Adly; Fatma Soliman ElSayed Ebeid; Deena Samir Eissa; Eman Abdel Rahman Ismail; Yasser Hassan Mohammed; Manar Elsayed Ahmed; Aya Sayed Saad
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

6.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

7.  Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease.

Authors:  Jason W Rosch; Angela R Boyd; Ernesto Hinojosa; Tamara Pestina; Yunming Hu; Derek A Persons; Carlos J Orihuela; Elaine I Tuomanen
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

8.  Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell disease.

Authors:  Steven M Szczepanek; Jeffrey T McNamara; Eric R Secor; Prabitha Natarajan; Linda A Guernsey; Lauren A Miller; Enrique Ballesteros; Evan Jellison; Roger S Thrall; Biree Andemariam
Journal:  Am J Pathol       Date:  2012-09-19       Impact factor: 4.307

9.  Histopathology of experimentally induced asthma in a murine model of sickle cell disease.

Authors:  Sandhya D Nandedkar; Thomas R Feroah; William Hutchins; Dorothee Weihrauch; Kameswari S Konduri; Jingli Wang; Robert C Strunk; Michael R DeBaun; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.